{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T22:04:49Z","timestamp":1791669889020,"version":"4.3.4"},"reference-count":136,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2018,7,31]],"date-time":"2018-07-31T00:00:00Z","timestamp":1532995200000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"DOI":"10.3389\/fimmu.2018.01717","type":"journal-article","created":{"date-parts":[[2018,7,31]],"date-time":"2018-07-31T15:45:17Z","timestamp":1533051917000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":76,"title":["Immune Cell Hacking: Challenges and Clinical Approaches to Create Smarter Generations of Chimeric Antigen Receptor T Cells"],"prefix":"10.3389","volume":"9","author":[{"given":"Reza","family":"Elahi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elnaz","family":"Khosh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Safa","family":"Tahmasebi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdolreza","family":"Esmaeilzadeh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2018,7,31]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1093\/jnci\/djx145","article-title":"Use of alternative medicine for cancer and its impact on survival","volume":"110","author":"Johnson","year":"2018","journal-title":"J Natl Cancer Inst"},{"key":"B2","doi-asserted-by":"publisher","first-page":"154","DOI":"10.3109\/08830185.2015.1018419","article-title":"Chimeric antigen receptor engineering: a right step in the evolution of adoptive cellular immunotherapy","volume":"34","author":"Figueroa","year":"2015","journal-title":"Int Rev Immunol"},{"key":"B3","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1038\/nm.3161","article-title":"Mining exomic sequencing data to identify mutated antigens recognized by adoptively transferred tumor-reactive T cells","volume":"19","author":"Robbins","year":"2013","journal-title":"Nat Med"},{"key":"B4","doi-asserted-by":"publisher","first-page":"1770","DOI":"10.3389\/fimmu.2017.01770","article-title":"Mesenchymal stromal\/stem cells: a new era in the cell-based targeted gene therapy of cancer","volume":"8","author":"Marofi","year":"2017","journal-title":"Front Immunol"},{"key":"B5","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1186\/s13045-017-0444-9","article-title":"Chimeric antigen receptor T cells: a novel therapy for solid tumors","volume":"10","author":"Yu","year":"2017","journal-title":"J Hematol Oncol"},{"key":"B6","doi-asserted-by":"publisher","first-page":"264","DOI":"10.2174\/1874467208666150716121253","article-title":"Novel immunotherapies for hematological malignancies","volume":"9","author":"Vasekar","year":"2016","journal-title":"Curr Mol Pharmacol"},{"key":"B7","doi-asserted-by":"publisher","first-page":"10024","DOI":"10.1073\/pnas.86.24.10024","article-title":"Expression of immunoglobulin-T-cell receptor chimeric molecules as functional receptors with antibody-type specificity","volume":"86","author":"Gross","year":"1989","journal-title":"Proc Natl Acad Sci U S A"},{"key":"B8","doi-asserted-by":"publisher","first-page":"1229","DOI":"10.1089\/hum.2009.142","article-title":"Fifteen years of gene therapy based on chimeric antigen receptors: \u201care we nearly there yet?\u201d","volume":"20","author":"Dotti","year":"2009","journal-title":"Hum Gene Ther"},{"key":"B9","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1016\/j.tips.2015.11.004","article-title":"Adoptive T cell therapies: a comparison of T cell receptors and chimeric antigen receptors","volume":"37","author":"Harris","year":"2016","journal-title":"Trends Pharmacol Sci"},{"key":"B10","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13045-016-0379-6","article-title":"A new insight in chimeric antigen receptor-engineered T cells for cancer immunotherapy","volume":"10","author":"Zhang","year":"2017","journal-title":"J Hematol Oncol"},{"key":"B11","doi-asserted-by":"publisher","first-page":"1822","DOI":"10.1172\/JCI46110","article-title":"CD28 costimulation improves expansion and persistence of chimeric antigen receptor\u2013modified T cells in lymphoma patients","volume":"121","author":"Savoldo","year":"2011","journal-title":"J Clin Invest"},{"key":"B12","doi-asserted-by":"publisher","first-page":"7513687","DOI":"10.1155\/2017\/7513687","article-title":"Immunooncology: can the right chimeric antigen receptors T-cell design be made to cure all types of cancers and will it be covered?","volume":"2017","author":"Au","year":"2017","journal-title":"J Pharm"},{"key":"B13","doi-asserted-by":"publisher","first-page":"1160","DOI":"10.1038\/leu.2010.75","article-title":"Engineering CD19-specific T lymphocytes with interleukin-15 and a suicide gene to enhance their anti-lymphoma\/leukemia effects and safety","volume":"24","author":"Hoyos","year":"2010","journal-title":"Leukemia"},{"key":"B14","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1016\/j.omtm.2016.12.006","article-title":"Global manufacturing of CAR T cell therapy","volume":"4","author":"Levine","year":"2017","journal-title":"Mol Ther Methods Clin Dev"},{"key":"B15","doi-asserted-by":"publisher","first-page":"4656","DOI":"10.1038\/srep04656","article-title":"Non-integrating gamma-retroviral vectors as a versatile tool for transient zinc-finger nuclease delivery","volume":"4","author":"Bobis-Wozowicz","year":"2014","journal-title":"Sci Rep"},{"key":"B16","doi-asserted-by":"publisher","first-page":"677","DOI":"10.3390\/v3060677","article-title":"Gammaretroviral vectors: biology, technology and application","volume":"3","author":"Maetzig","year":"2011","journal-title":"Viruses"},{"key":"B17","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1007\/978-3-642-56114-6_5","volume-title":"Production of Lentiviral Vectors","author":"Zufferey","year":"2002"},{"key":"B18","doi-asserted-by":"publisher","first-page":"1101","DOI":"10.1126\/science.aah6192","article-title":"Lentiviral vectors, two decades later","volume":"353","author":"Naldini","year":"2016","journal-title":"Science"},{"key":"B19","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1038\/leu.2016.180","article-title":"Enhanced CAR T-cell engineering using non-viral sleeping beauty transposition from minicircle vectors","volume":"31","author":"Monjezi","year":"2017","journal-title":"Leukemia"},{"key":"B20","first-page":"37","volume-title":"Minicircle-Based Engineering of Chimeric Antigen Receptor (CAR) T Cells. Current Strategies in Cancer Gene Therapy","author":"Hudecek","year":"2016"},{"key":"B21","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1089\/hum.2005.16.126","article-title":"Improved production and purification of minicircle DNA vector free of plasmid bacterial sequences and capable of persistent transgene expression in vivo","volume":"16","author":"Chen","year":"2005","journal-title":"Hum Gene Ther"},{"key":"B22","doi-asserted-by":"publisher","first-page":"1287","DOI":"10.1038\/nbt.1708","article-title":"A robust system for production of minicircle DNA vectors","volume":"28","author":"Kay","year":"2010","journal-title":"Nat Biotechnol"},{"key":"B23","doi-asserted-by":"publisher","first-page":"614","DOI":"10.1089\/hum.2017.080","article-title":"Development of anti-human mesothelin-targeted chimeric antigen receptor messenger RNA\u2013transfected peripheral blood lymphocytes for ovarian cancer therapy","volume":"29","author":"Hung","year":"2018","journal-title":"Hum Gene Ther"},{"key":"B24","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1186\/s40364-017-0102-y","article-title":"Engineering CAR-T cells","volume":"5","author":"Zhang","year":"2017","journal-title":"Biomark Res"},{"key":"B25","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/j.jmhi.2014.05.002","article-title":"IL-24: a novel gene therapy candidate for immune system upregulation in Hodgkin\u2019s lymphoma","volume":"9","author":"Manesh","year":"2015","journal-title":"J Med Hypoth Ideas"},{"key":"B26","doi-asserted-by":"publisher","first-page":"1002","DOI":"10.1016\/j.jcyt.2016.05.009","article-title":"Automated manufacturing of chimeric antigen receptor T cells for adoptive immunotherapy using CliniMACS prodigy","volume":"18","author":"Mock","year":"2016","journal-title":"Cytotherapy"},{"key":"B27","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1038\/cgt.2014.81","article-title":"Manufacture of tumor- and virus-specific T lymphocytes for adoptive cell therapies","volume":"22","author":"Wang","year":"2015","journal-title":"Cancer Gene Ther"},{"key":"B28","doi-asserted-by":"publisher","first-page":"1433","DOI":"10.1007\/s00262-016-1895-5","article-title":"The growing world of CAR T cell trials: a systematic review","volume":"65","author":"Holzinger","year":"2016","journal-title":"Cancer Immunol Immunother"},{"key":"B29","doi-asserted-by":"publisher","first-page":"ra151","DOI":"10.1126\/scitranslmed.3010162","article-title":"Regional delivery of mesothelin-targeted CAR T cell therapy generates potent and long-lasting CD4-dependent tumor immunity","volume":"6","author":"Adusumilli","year":"2014","journal-title":"Sci Transl Med"},{"key":"B30","doi-asserted-by":"publisher","first-page":"3149","DOI":"10.1158\/1078-0432.CCR-14-1421","article-title":"Phase I hepatic immunotherapy for metastases study of intra-arterial chimeric antigen receptor\u2013modified T-cell therapy for CEA+ liver metastases","volume":"21","author":"Katz","year":"2015","journal-title":"Clin Cancer Res"},{"key":"B31","doi-asserted-by":"publisher","first-page":"TPS4700","DOI":"10.1200\/jco.2012.30.15\\_suppl.tps4700","article-title":"Targeting castration resistant prostate cancer (CRPC) with autologous PSMA-directed CAR+ T cells","volume":"30","author":"Slovin","year":"2012","journal-title":"Am Soc Clin Oncol"},{"key":"B32","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1016\/S1074-7613(00)80268-X","article-title":"Identification of the earliest B lineage stage in mouse bone marrow","volume":"5","author":"Li","year":"1996","journal-title":"Immunity"},{"key":"B33","doi-asserted-by":"publisher","first-page":"1509","DOI":"10.1056\/NEJMoa1215134","article-title":"Chimeric antigen receptor\u2013modified T cells for acute lymphoid leukemia","volume":"368","author":"Grupp","year":"2013","journal-title":"N Engl J Med"},{"key":"B34","doi-asserted-by":"publisher","first-page":"e1027469","DOI":"10.1080\/2162402X.2015.1027469","article-title":"Tolerance and efficacy of autologous or donor-derived T cells expressing CD19 chimeric antigen receptors in adult B-ALL with extramedullary leukemia","volume":"4","author":"Dai","year":"2015","journal-title":"Oncoimmunology"},{"key":"B35","doi-asserted-by":"publisher","first-page":"2123","DOI":"10.1172\/JCI85309","article-title":"CD19 CAR\u2013T cells of defined CD4+: CD8+ composition in adult B cell ALL patients","volume":"126","author":"Turtle","year":"2016","journal-title":"J Clin Invest"},{"key":"B36","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1200\/JCO.2014.56.2025","article-title":"Chemotherapy-refractory diffuse large B-cell lymphoma and indolent B-cell malignancies can be effectively treated with autologous T cells expressing an anti-CD19 chimeric antigen receptor","volume":"33","author":"Kochenderfer","year":"2014","journal-title":"J Clin Oncol"},{"key":"B37","doi-asserted-by":"publisher","first-page":"1040","DOI":"10.1056\/NEJMoa1504542","article-title":"Chimeric antigen receptor T cells against CD19 for multiple myeloma","volume":"373","author":"Garfall","year":"2015","journal-title":"N Engl J Med"},{"key":"B38","doi-asserted-by":"publisher","first-page":"2594","DOI":"10.1182\/blood-2017-06-793869","article-title":"Chimeric antigen receptor T-cell therapies for multiple myeloma","volume":"130","author":"Mikkilineni","year":"2017","journal-title":"Blood"},{"key":"B39","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1016\/j.jocit.2014.11.001","article-title":"CD138-directed adoptive immunotherapy of chimeric antigen receptor (CAR)-modified T cells for multiple myeloma","volume":"2","author":"Guo","year":"2016","journal-title":"J Cell Immunother"},{"key":"B40","doi-asserted-by":"publisher","first-page":"ra139","DOI":"10.1126\/scitranslmed.aac5415","article-title":"Chimeric antigen receptor T cells persist and induce sustained remissions in relapsed refractory chronic lymphocytic leukemia","volume":"7","author":"Porter","year":"2015","journal-title":"Sci Transl Med"},{"key":"B41","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1038\/mt.2014.164","article-title":"Treatment of CD33-directed chimeric antigen receptor-modified T cells in one patient with relapsed and refractory acute myeloid leukemia","volume":"23","author":"Wang","year":"2015","journal-title":"Mol Ther"},{"key":"B42","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1038\/nm.4441","article-title":"CD22-targeted CAR T cells induce remission in B-ALL that is naive or resistant to CD19-targeted CAR immunotherapy","volume":"24","author":"Fry","year":"2018","journal-title":"Nat Med"},{"key":"B43","doi-asserted-by":"publisher","first-page":"16002","DOI":"10.1038\/sigtrans.2016.2","article-title":"Treatment of CD20-directed chimeric antigen receptor-modified T cells in patients with relapsed or refractory B-cell non-Hodgkin lymphoma: an early phase IIa trial report","volume":"1","author":"Zhang","year":"2016","journal-title":"Signal Transduct Target Ther"},{"key":"B44","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1080\/14712598.2017.1322953","article-title":"Regulatory challenges and considerations for the clinical application of CAR-T cell anti-cancer therapy","volume":"17","author":"Locke","year":"2017","journal-title":"Expert Opin Biol Ther"},{"key":"B45","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1146\/annurev-med-062315-120245","article-title":"CAR T cell therapy for solid tumors","volume":"68","author":"Newick","year":"2017","journal-title":"Annu Rev Med"},{"key":"B46","doi-asserted-by":"publisher","first-page":"468","DOI":"10.1007\/s11427-016-5023-8","article-title":"Chimeric antigen receptor-modified T cells for the immunotherapy of patients with EGFR-expressing advanced relapsed\/refractory non-small cell lung cancer","volume":"59","author":"Feng","year":"2016","journal-title":"Sci China Life Sci"},{"key":"B47","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1158\/1078-0432.CCR-09-1322","article-title":"HER2-specific T cells target primary glioblastoma stem cells and induce regression of autologous experimental tumors","volume":"16","author":"Ahmed","year":"2010","journal-title":"Clin Cancer Res"},{"key":"B48","doi-asserted-by":"publisher","first-page":"62730","DOI":"10.18632\/oncotarget.17528","article-title":"Driving better and safer HER2-specific CARs for cancer therapy","volume":"37","author":"Liu","year":"2017","journal-title":"Oncotarget"},{"key":"B49","doi-asserted-by":"publisher","first-page":"5957","DOI":"10.1158\/0008-5472.CAN-06-4309","article-title":"Regression of experimental medulloblastoma following transfer of HER2-specific T cells","volume":"67","author":"Ahmed","year":"2007","journal-title":"Cancer Res"},{"key":"B50","doi-asserted-by":"publisher","first-page":"1779","DOI":"10.1038\/mt.2009.133","article-title":"Immunotherapy for osteosarcoma: genetic modification of T cells overcomes low levels of tumor antigen expression","volume":"17","author":"Ahmed","year":"2009","journal-title":"Mol Ther"},{"key":"B51","doi-asserted-by":"publisher","first-page":"R61","DOI":"10.1186\/bcr3674","article-title":"Construction and evaluation of a novel humanized HER2-specific chimeric receptor","volume":"16","author":"Sun","year":"2014","journal-title":"Breast Cancer Res"},{"key":"B52","doi-asserted-by":"publisher","first-page":"1688","DOI":"10.1200\/JCO.2014.58.0225","article-title":"Human epidermal growth factor receptor 2 (HER2)-specific chimeric antigen receptor-modified T cells for the immunotherapy of HER2-positive sarcoma","volume":"33","author":"Ahmed","year":"2015","journal-title":"J Clin Oncol"},{"key":"B53","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1186\/s12967-015-0460-x","article-title":"A phase I clinical trial of adoptive T cell therapy using IL-12 secreting MUC-16 ecto directed chimeric antigen receptors for recurrent ovarian cancer","volume":"13","author":"Koneru","year":"2015","journal-title":"J Transl Med"},{"key":"B54","doi-asserted-by":"publisher","first-page":"10541","DOI":"10.1038\/s41598-017-10940-8","article-title":"Armored CAR T cells enhance antitumor efficacy and overcome the tumor microenvironment","volume":"7","author":"Yeku","year":"2017","journal-title":"Sci Rep"},{"key":"B55","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1038\/nrclinonc.2018.20","article-title":"Chimeric antigen receptor T-cell therapy\u2014assessment and management of toxicities","volume":"15","author":"Neelapu","year":"2018","journal-title":"Nat Rev Clin Oncol"},{"key":"B56","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1038\/mt.2010.24","article-title":"Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2","volume":"18","author":"Morgan","year":"2010","journal-title":"Mol Ther"},{"key":"B57","doi-asserted-by":"publisher","first-page":"3321","DOI":"10.1182\/blood-2016-04-703751","article-title":"Toxicities of chimeric antigen receptor T cells: recognition and management","volume":"127","author":"Brudno","year":"2016","journal-title":"Blood"},{"key":"B58","doi-asserted-by":"publisher","first-page":"664","DOI":"10.1158\/2159-8290.CD-16-0040","article-title":"Identification of predictive biomarkers for cytokine release syndrome after chimeric antigen receptor T cell therapy for acute lymphoblastic leukemia","volume":"6","author":"Teachey","year":"2016","journal-title":"Cancer Discov"},{"key":"B59","doi-asserted-by":"publisher","first-page":"16011","DOI":"10.1038\/mto.2016.11","article-title":"Toxicity and management in CAR T-cell therapy","volume":"3","author":"Bonifant","year":"2016","journal-title":"Mol Ther Oncolytics"},{"key":"B60","first-page":"802","article-title":"CD19-Targeted CAR T cells as novel cancer immunotherapy for relapsed or refractory B-cell acute lymphoblastic leukemia","volume":"14","author":"Davila","year":"2016","journal-title":"Clin Adv Hematol Oncol"},{"key":"B61","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1186\/s13045-016-0299-5","article-title":"Predominant cerebral cytokine release syndrome in CD19-directed chimeric antigen receptor-modified T cell therapy","volume":"9","author":"Hu","year":"2016","journal-title":"J Hematol Oncol"},{"key":"B62","doi-asserted-by":"publisher","first-page":"61","DOI":"10.2165\/00003088-200544010-00003","article-title":"Pharmacokinetics and pharmacodynamics of systemically administered glucocorticoids","volume":"44","author":"Czock","year":"2005","journal-title":"Clin Pharmacokinet"},{"key":"B63","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1158\/2326-6066.CIR-13-0006","article-title":"T cells expressing chimeric antigen receptors can cause anaphylaxis in humans","volume":"1","author":"Maus","year":"2013","journal-title":"Cancer Immunol Res"},{"key":"B64","doi-asserted-by":"publisher","first-page":"ra53","DOI":"10.1126\/scitranslmed.3003761","article-title":"Decade-long safety and function of retroviral-modified chimeric antigen receptor T cells","volume":"4","author":"Scholler","year":"2012","journal-title":"Sci Transl Med"},{"key":"B65","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1126\/science.1088547","article-title":"LMO2-associated clonal T cell proliferation in two patients after gene therapy for SCID-X1","volume":"302","author":"Hacein-Bey-Abina","year":"2003","journal-title":"Science"},{"key":"B66","doi-asserted-by":"publisher","first-page":"3132","DOI":"10.1172\/JCI35700","article-title":"Insertional oncogenesis in 4 patients after retrovirus-mediated gene therapy of SCID-X1","volume":"118","author":"Hacein-Bey-Abina","year":"2008","journal-title":"J Clin Invest"},{"key":"B67","doi-asserted-by":"publisher","first-page":"634","DOI":"10.1007\/s13238-017-0410-x","article-title":"Advancing chimeric antigen receptor T cell therapy with CRISPR\/Cas9","volume":"8","author":"Ren","year":"2017","journal-title":"Protein Cell"},{"key":"B68","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1038\/s41598-017-00462-8","article-title":"CRISPR\/Cas9-mediated PD-1 disruption enhances anti-tumor efficacy of human chimeric antigen receptor T cells","volume":"7","author":"Rupp","year":"2017","journal-title":"Sci Rep"},{"key":"B69","doi-asserted-by":"publisher","first-page":"1469","DOI":"10.1080\/14712598.2016.1235148","article-title":"From therapeutic antibodies to chimeric antigen receptors (CARs): making better CARs based on antigen-binding domain","volume":"16","author":"Wu","year":"2016","journal-title":"Expert Opin Biol Ther"},{"key":"B70","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1186\/s13045-017-0423-1","article-title":"New development in CAR-T cell therapy","volume":"10","author":"Wang","year":"2017","journal-title":"J Hematol Oncol"},{"key":"B71","doi-asserted-by":"publisher","first-page":"1788","DOI":"10.1038\/leu.2016.373","article-title":"Optimized T-cell receptor-mimic chimeric antigen receptor T cells directed toward the intracellular Wilms Tumor 1 antigen","volume":"31","author":"Rafiq","year":"2017","journal-title":"Leukemia"},{"key":"B72","doi-asserted-by":"publisher","first-page":"77","DOI":"10.4161\/mabs.2.1.10786","article-title":"Antibody fragments: hope and hype","volume":"2","author":"Nelson","year":"2010","journal-title":"MAbs"},{"key":"B73","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1038\/nbt0409-331","article-title":"Development trends for therapeutic antibody fragments","volume":"27","author":"Nelson","year":"2009","journal-title":"Nat Biotechnol"},{"key":"B74","doi-asserted-by":"publisher","first-page":"3571","DOI":"10.1038\/srep03571","article-title":"Anti-melanoma activity of T cells redirected with a TCR-like chimeric antigen receptor","volume":"4","author":"Zhang","year":"2014","journal-title":"Sci Rep"},{"key":"B75","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1007\/s13238-017-0394-6","article-title":"Targeting cancer stem cells by using chimeric antigen receptor-modified T cells: a potential and curable approach for cancer treatment","volume":"9","author":"Guo","year":"2018","journal-title":"Protein Cell"},{"key":"B76","doi-asserted-by":"publisher","first-page":"13545","DOI":"10.18632\/oncotarget.14592","article-title":"Intraperitoneal immunotherapy with T cells stably and transiently expressing anti-EpCAM CAR in xenograft models of peritoneal carcinomatosis","volume":"8","author":"Ang","year":"2017","journal-title":"Oncotarget"},{"key":"B77","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12865-014-0064-x","article-title":"Adoptive T-cell therapy of prostate cancer targeting the cancer stem cell antigen EpCAM","volume":"16","author":"Deng","year":"2015","journal-title":"BMC Immunol"},{"key":"B78","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1093\/glycob\/cwy008","article-title":"Glycan-directed CAR-T cells","volume":"1","author":"Steentoft","year":"2018","journal-title":"Glycobiology"},{"key":"B79","doi-asserted-by":"publisher","first-page":"1145","DOI":"10.1517\/14712598.2015.1046430","article-title":"TRUCKs: the fourth generation of CARs","volume":"15","author":"Chmielewski","year":"2015","journal-title":"Expert Opin Biol Ther"},{"key":"B80","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1158\/2159-8290.CD-12-0548","article-title":"The basic principles of chimeric antigen receptor design","volume":"3","author":"Sadelain","year":"2013","journal-title":"Cancer Discov"},{"key":"B81","doi-asserted-by":"publisher","first-page":"2255","DOI":"10.1158\/1078-0432.CCR-16-1300","article-title":"Multiplex genome editing to generate universal CAR T cells resistant to PD1 inhibition","volume":"23","author":"Ren","year":"2017","journal-title":"Clin Cancer Res"},{"key":"B82","doi-asserted-by":"publisher","first-page":"e019321","DOI":"10.1136\/bmjopen-2017-019321","article-title":"Efficacy and safety of chimeric antigen receptor T-cell (CAR-T) therapy in patients with haematological and solid malignancies: protocol for a systematic review and meta-analysis","volume":"7","author":"Grigor","year":"2017","journal-title":"BMJ Open"},{"key":"B83","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.5779\/hypothesis.v14i1.456","article-title":"IL-1R2: a novel approach for gene therapy in atherosclerosis","volume":"14","author":"Ahmadi","year":"2016","journal-title":"Atherosclerosis"},{"key":"B84","doi-asserted-by":"publisher","first-page":"1245","DOI":"10.1016\/j.bbmt.2010.03.014","article-title":"Antitransgene rejection responses contribute to attenuated persistence of adoptively transferred CD20\/CD19-specific chimeric antigen receptor redirected T cells in humans","volume":"16","author":"Jensen","year":"2010","journal-title":"Biol Blood Marrow Transplant"},{"key":"B85","doi-asserted-by":"publisher","first-page":"235","DOI":"10.3389\/fphar.2014.00235","article-title":"The inducible caspase-9 suicide gene system as a \u201csafety switch\u201d to limit on-target, off-tumor toxicities of chimeric antigen receptor T cells","volume":"5","author":"Gargett","year":"2014","journal-title":"Front Pharmacol"},{"key":"B86","doi-asserted-by":"publisher","first-page":"E459","DOI":"10.1073\/pnas.1524155113","article-title":"Switch-mediated activation and retargeting of CAR-T cells for B-cell malignancies","volume":"113","author":"Rodgers","year":"2016","journal-title":"Proc Natl Acad Sci U S A"},{"key":"B87","doi-asserted-by":"publisher","first-page":"566","DOI":"10.1038\/nrc.2016.97","article-title":"Engineered T cells: the promise and challenges of cancer immunotherapy","volume":"16","author":"Fesnak","year":"2016","journal-title":"Nat Rev Cancer"},{"key":"B88","doi-asserted-by":"publisher","first-page":"780","DOI":"10.1016\/j.cell.2016.01.012","article-title":"Engineering customized cell sensing and response behaviors using synthetic notch receptors","volume":"164","author":"Morsut","year":"2016","journal-title":"Cell"},{"key":"B89","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1186\/s40425-017-0230-9","article-title":"Current approaches to increase CAR T cell potency in solid tumors: targeting the tumor microenvironment","volume":"5","author":"Scarf\u00f2","year":"2017","journal-title":"J Immunother Cancer"},{"key":"B90","doi-asserted-by":"publisher","first-page":"ra172","DOI":"10.1126\/scitranslmed.3006597","article-title":"PD-1- and CTLA-4-based inhibitory chimeric antigen receptors (iCARs) divert off-target immunotherapy responses","volume":"5","author":"Fedorov","year":"2013","journal-title":"Sci Transl Med"},{"key":"B91","doi-asserted-by":"publisher","first-page":"e89580","DOI":"10.1172\/jci.insight.89580","article-title":"Transient stimulation expands superior antitumor T cells for adoptive therapy","volume":"2","author":"Kagoya","year":"2017","journal-title":"JCI Insight"},{"key":"B92","doi-asserted-by":"publisher","first-page":"1277","DOI":"10.1182\/blood-2014-01-545020","article-title":"A highly compact epitope-based marker\/suicide gene for easier and safer T-cell therapy","volume":"124","author":"Philip","year":"2014","journal-title":"Blood"},{"key":"B93","doi-asserted-by":"publisher","first-page":"1255","DOI":"10.1182\/blood-2011-02-337360","article-title":"A transgene-encoded cell surface polypeptide for selection, in vivo tracking, and ablation of engineered cells","volume":"118","author":"Wang","year":"2011","journal-title":"Blood"},{"key":"B94","doi-asserted-by":"publisher","first-page":"e105","DOI":"10.1038\/mtna.2013.32","article-title":"TanCAR: a novel bispecific chimeric antigen receptor for cancer immunotherapy","volume":"2","author":"Grada","year":"2013","journal-title":"Mol Ther Nucleic Acids"},{"key":"B95","doi-asserted-by":"publisher","first-page":"O3","DOI":"10.1186\/2051-1426-3-S2-O3","article-title":"A bispecific chimeric antigen receptor molecule enhances T cell activation through dual immunological synapse formation and offsets antigen escape in glioblastoma","volume":"3","author":"Hegde","year":"2015","journal-title":"J Immunother Cancer"},{"key":"B96","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1158\/2326-6066.CIR-13-0008","article-title":"Chimeric antigen receptor T Cells with dissociated signaling domains exhibit focused antitumor activity with reduced potential for toxicity in vivo","volume":"1","author":"Lanitis","year":"2013","journal-title":"Cancer Immunol Res"},{"key":"B97","doi-asserted-by":"publisher","first-page":"1059","DOI":"10.1007\/s10875-012-9689-9","article-title":"Dual targeting of ErbB2 and MUC1 in breast cancer using chimeric antigen receptors engineered to provide complementary signaling","volume":"32","author":"Wilkie","year":"2012","journal-title":"J Clin Immunol"},{"key":"B98","doi-asserted-by":"publisher","first-page":"3036","DOI":"10.1172\/JCI83416","article-title":"Tandem CAR T cells targeting HER2 and IL13R\u03b12 mitigate tumor antigen escape","volume":"126","author":"Hegde","year":"2016","journal-title":"J Clin Invest"},{"key":"B99","doi-asserted-by":"publisher","first-page":"A193","DOI":"10.1158\/2326-6074.CRICIMTEATIAACR15-A193","article-title":"Abstract A193: bioengineered dectin-1 CAR+ T cells to control invasive fungal infection","volume":"4","author":"Kumaresan","year":"2016","journal-title":"AACR"},{"key":"B100","doi-asserted-by":"publisher","first-page":"39833","DOI":"10.1038\/srep39833","article-title":"An oxygen sensitive self-decision making engineered CAR T-cell","volume":"7","author":"Juillerat","year":"2017","journal-title":"Sci Rep"},{"key":"B101","doi-asserted-by":"publisher","first-page":"3953","DOI":"10.1172\/JCI43490","article-title":"Gene therapy using genetically modified lymphocytes targeting VEGFR-2 inhibits the growth of vascularized syngenic tumors in mice","volume":"120","author":"Chinnasamy","year":"2010","journal-title":"J Clin Invest"},{"key":"B102","doi-asserted-by":"publisher","first-page":"1672","DOI":"10.1158\/1078-0432.CCR-11-3050","article-title":"Local delivery of lnterleukin-12 using T cells targeting VEGF receptor-2 eradicates multiple vascularized tumors in mice","volume":"18","author":"Chinnasamy","year":"2012","journal-title":"Clinical Cancer Res"},{"key":"B103","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1016\/j.ymthe.2016.10.012","article-title":"Targeting of aberrant \u03b1v\u03b26 integrin expression in solid tumors using chimeric antigen receptor-engineered T cells","volume":"25","author":"Whilding","year":"2017","journal-title":"Mol Ther"},{"key":"B104","doi-asserted-by":"publisher","first-page":"626","DOI":"10.3324\/haematol.2015.135301","article-title":"Effects of anti-NKG2A antibody administration on leukemia and normal hematopoietic cells","volume":"101","author":"Ruggeri","year":"2016","journal-title":"Haematologica"},{"key":"B105","doi-asserted-by":"publisher","first-page":"e1273302","DOI":"10.1080\/2162402X.2016.1273302","article-title":"CAR T-cell intrinsic PD-1 checkpoint blockade: a two-in-one approach for solid tumor immunotherapy","volume":"6","author":"Chen","year":"2017","journal-title":"Oncoimmunology"},{"key":"B106","doi-asserted-by":"publisher","first-page":"929","DOI":"10.1172\/JCI89455","article-title":"Targeting the adenosine 2A receptor enhances chimeric antigen receptor T cell efficacy","volume":"127","author":"Beavis","year":"2017","journal-title":"J Clin Invest"},{"key":"B107","doi-asserted-by":"publisher","first-page":"759","DOI":"10.4049\/jimmunol.1401710","article-title":"Coexpressed catalase protects chimeric antigen receptor\u2013redirected T cells as well as bystander cells from oxidative stress-induced loss of antitumor activity","volume":"196","author":"Ligtenberg","year":"2016","journal-title":"J Immunol"},{"key":"B108","doi-asserted-by":"publisher","first-page":"1611","DOI":"10.1038\/mt.2013.110","article-title":"Antitumor effects of chimeric receptor engineered human T cells directed to tumor stroma","volume":"21","author":"Kakarla","year":"2013","journal-title":"Mol Ther"},{"key":"B109","doi-asserted-by":"publisher","first-page":"2800","DOI":"10.1158\/0008-5472.CAN-14-3041","article-title":"Tumor-promoting desmoplasia is disrupted by depleting FAP-expressing stromal cells","volume":"75","author":"Lo","year":"2015","journal-title":"Cancer Res"},{"key":"B110","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1016\/j.ymthe.2016.10.016","article-title":"Improving chimeric antigen receptor-modified T cell function by reversing the immunosuppressive tumor microenvironment of pancreatic cancer","volume":"25","author":"Mohammed","year":"2017","journal-title":"Mol Ther"},{"key":"B111","doi-asserted-by":"publisher","first-page":"5636","DOI":"10.1158\/1078-0432.CCR-13-0458","article-title":"Anti-PD-1 antibody therapy potently enhances the eradication of established tumors by gene-modified T cells","volume":"19","author":"John","year":"2013","journal-title":"Clin Cancer Res"},{"key":"B112","doi-asserted-by":"publisher","first-page":"1180","DOI":"10.1002\/adhm.201500089","article-title":"Ovarian cancer immunotherapy using PD-L1 siRNA targeted delivery from folic acid-functionalized polyethylenimine: strategies to enhance T cell killing","volume":"4","author":"Teo","year":"2015","journal-title":"Adv Healthc Mater"},{"key":"B113","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1002\/phar.1900","article-title":"Chimeric antigen receptor T cells in hematologic malignancies","volume":"37","author":"Shank","year":"2017","journal-title":"Pharmacotherapy"},{"key":"B114","doi-asserted-by":"publisher","first-page":"1994","DOI":"10.1016\/j.molonc.2015.10.012","article-title":"CAR T cell immunotherapy: the path from the by road to the freeway?","volume":"9","author":"Whilding","year":"2015","journal-title":"Mol Oncol"},{"key":"B115","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1186\/s13045-017-0405-3","article-title":"Allogeneic CD19-CAR-T cell infusion after allogeneic hematopoietic stem cell transplantation in B cell malignancies","volume":"10","author":"Liu","year":"2017","journal-title":"J Hematol Oncol"},{"key":"B116","doi-asserted-by":"publisher","first-page":"1183","DOI":"10.15252\/emmm.201607485","article-title":"Clinical development of CAR T cells\u2014challenges and opportunities in translating innovative treatment concepts","volume":"9","author":"Hartmann","year":"2017","journal-title":"EMBO Mol Med"},{"key":"B117","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1038\/cgt.2015.5","article-title":"Performance-enhancing drugs: design and production of redirected chimeric antigen receptor (CAR) T cells","volume":"22","author":"Levine","year":"2015","journal-title":"Cancer Gene Ther"},{"key":"B118","doi-asserted-by":"publisher","first-page":"92","DOI":"10.3390\/cancers9070092","article-title":"Regional delivery of chimeric antigen receptor (CAR) T-cells for cancer therapy","volume":"9","author":"Sridhar","year":"2017","journal-title":"Cancers."},{"key":"B119","doi-asserted-by":"publisher","first-page":"16015","DOI":"10.1038\/mto.2016.15","article-title":"Clinical manufacturing of CAR T cells: foundation of a promising therapy","volume":"3","author":"Wang","year":"2016","journal-title":"Mol Ther Oncolytics"},{"key":"B120","doi-asserted-by":"publisher","first-page":"608","DOI":"10.1634\/theoncologist.2015-0421","article-title":"Chimeric antigen receptor T-cell therapy for the community oncologist","volume":"21","author":"Maus","year":"2016","journal-title":"Oncologist"},{"key":"B121","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1038\/nbt0117-6b","article-title":"CAR-T\u2019s forge ahead, despite Juno deaths","volume":"35","author":"DeFrancesco","year":"2017","journal-title":"Nat Biotechnol"},{"key":"B122","first-page":"13","article-title":"Induction of allogeneic subcutaneous glioma tumor with GL 26 cell line in Balb\/c mice","volume":"20","author":"Esmaeilzadeh","year":"2012","journal-title":"ZUMS J"},{"key":"B123","first-page":"4558","article-title":"Defined central memory and stem memory T cell phenotype of CD4 and CD8 CAR T cells for the treatment of CD19+ acute lymphoblastic leukemia in an automated closed system","volume":"128","author":"Blaeschke","year":"2016","journal-title":"Am Soc Hematol"},{"key":"B124","doi-asserted-by":"publisher","first-page":"56219","DOI":"10.18632\/oncotarget.11019","article-title":"Novel anti-CD3 chimeric antigen receptor targeting of aggressive T cell malignancies","volume":"7","author":"Chen","year":"2016","journal-title":"Oncotarget"},{"key":"B125","doi-asserted-by":"publisher","first-page":"e26286","DOI":"10.4161\/onci.26286","article-title":"Blockade of PD-1 immunosuppression boosts CAR T-cell therapy","volume":"2","author":"John","year":"2013","journal-title":"Oncoimmunology"},{"key":"B126","doi-asserted-by":"publisher","first-page":"1","DOI":"10.7889\/hct.6.1","article-title":"CAR-T cell therapy in combination with allogeneic stem cell transplantation","volume":"6","author":"Terakura","year":"2017","journal-title":"J Hematopoietic Cell Transplant"},{"key":"B127","doi-asserted-by":"publisher","first-page":"724","DOI":"10.1016\/j.cell.2017.01.016","article-title":"The principles of engineering immune cells to treat cancer","volume":"168","author":"Lim","year":"2017","journal-title":"Cell"},{"key":"B128","doi-asserted-by":"publisher","first-page":"892","DOI":"10.1002\/ajh.24794","article-title":"Chimeric antigen receptor modified T cells that target chemokine receptor Ccr4 as a therapeutic modality for T-cell malignancies","volume":"92","author":"Perera","year":"2017","journal-title":"Am J Hematol"},{"key":"B129","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1158\/2326-6066.CIR-15-0231","article-title":"T cells expressing CD19\/CD20 bi-specific chimeric antigen receptors prevent antigen escape by malignant B cells","volume":"4","author":"Zah","year":"2016","journal-title":"Cancer Immunol Res"},{"key":"B130","doi-asserted-by":"publisher","first-page":"ra25","DOI":"10.1126\/scitranslmed.3008226","article-title":"Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia","volume":"6","author":"Davila","year":"2014","journal-title":"Sci Transl Med"},{"key":"B131","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1158\/2326-6066.CIR-13-0027","article-title":"Targeting fibroblast activation protein in tumor stroma with chimeric antigen receptor T cells can inhibit tumor growth and augment host immunity without severe toxicity","volume":"2","author":"Wang","year":"2014","journal-title":"Cancer Immunol Res"},{"key":"B132","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1038\/nm.3833","article-title":"Heparanase promotes tumor infiltration and antitumor activity of CAR-redirected T lymphocytes","volume":"21","author":"Caruana","year":"2015","journal-title":"Nat Med"},{"key":"B133","doi-asserted-by":"publisher","first-page":"1112","DOI":"10.1200\/JCO.2015.64.5929","article-title":"Allogeneic T cells that express an anti-CD19 chimeric antigen receptor induce remissions of B-cell malignancies that progress after allogeneic hematopoietic stem-cell transplantation without causing graft-versus-host disease","volume":"34","author":"Brudno","year":"2016","journal-title":"J Clin Oncol"},{"key":"B134","doi-asserted-by":"publisher","first-page":"3915","DOI":"10.1158\/0008-5472.CAN-09-3845","article-title":"Combining CD19 redirection and alloanergization to generate tumor-specific human T cells for allogeneic cell therapy of B-cell malignancies","volume":"70","author":"Davies","year":"2010","journal-title":"Cancer Res"},{"key":"B135","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1038\/nm.4258","article-title":"Donor CD19 CAR T cells exert potent graft-versus-lymphoma activity with diminished graft-versus-host activity","volume":"23","author":"Ghosh","year":"2017","journal-title":"Nat Med"},{"key":"B136","doi-asserted-by":"publisher","first-page":"1612","DOI":"10.1182\/blood-2012-09-457531","article-title":"T cells from CLL patients exhibit features of T-cell exhaustion but retain capacity for cytokine production","volume":"121","author":"Riches","year":"2013","journal-title":"Blood"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fimmu.2018.01717\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2018,7,31]],"date-time":"2018-07-31T15:45:23Z","timestamp":1533051923000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fimmu.2018.01717\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,7,31]]},"references-count":136,"alternative-id":["10.3389\/fimmu.2018.01717"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2018.01717","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,7,31]]},"article-number":"1717"}}